A DNA vaccine encoding foot-and-mouth disease virus B and T-cell epitopes targeted to class II swine leukocyte antigens protects pigs against viral challenge

Belén Borrego; Jordi M Argilaguet; Eva Pérez-Martín; Javier Dominguez; Mariano Pérez-Filgueira; José M Escribano; Francisco Sobrino; Fernando Rodriguez

doi:10.1016/j.antiviral.2011.07.017

A DNA vaccine encoding foot-and-mouth disease virus B and T-cell epitopes targeted to class II swine leukocyte antigens protects pigs against viral challenge

Antiviral Res. 2011 Nov;92(2):359-63. doi: 10.1016/j.antiviral.2011.07.017. Epub 2011 Jul 26.

Authors

Belén Borrego¹, Jordi M Argilaguet, Eva Pérez-Martín, Javier Dominguez, Mariano Pérez-Filgueira, José M Escribano, Francisco Sobrino, Fernando Rodriguez

Affiliation

¹ CISA-INIA, Valdeolmos, 28130 Madrid, Spain.

PMID: 21820470
DOI: 10.1016/j.antiviral.2011.07.017

Abstract

Development of efficient and safer vaccines against foot-and-mouth disease virus (FMDV) is a must. Previous results obtained in our laboratory have demonstrated that DNA vaccines encoding B and T cell epitopes from type C FMDV, efficiently controlled virus replication in mice, while they did not protect against FMDV challenge in pigs, one of the FMDV natural hosts. The main finding of this work is the ability to improve the protection afforded in swine using a new DNA-vaccine prototype (pCMV-APCH1BTT), encoding FMDV B and T-cell epitopes fused to the single-chain variable fragment of the 1F12 mouse monoclonal antibody that recognizes Class-II Swine Leukocyte antigens. Half of the DNA-immunized pigs were fully protected upon viral challenge, while the remaining animals were partially protected, showing a delayed, shorter and milder disease than control pigs. Full protection in a given vaccinated-pig correlated with the induction of specific IFNγ-secreting T-cells, detectable prior to FMDV-challenge, together with a rapid development of neutralizing antibodies after viral challenge, pointing towards the relevance that both arms of the immune response can play in protection. Our results open new avenues for developing future FMDV subunit vaccines.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Animals
Antibodies, Neutralizing / blood
Antibodies, Viral / blood
Epitopes, B-Lymphocyte / genetics
Epitopes, B-Lymphocyte / immunology*
Epitopes, T-Lymphocyte / genetics
Epitopes, T-Lymphocyte / immunology*
Foot-and-Mouth Disease / immunology
Foot-and-Mouth Disease / pathology
Foot-and-Mouth Disease / prevention & control*
Foot-and-Mouth Disease Virus / genetics
Foot-and-Mouth Disease Virus / immunology*
Histocompatibility Antigens Class II / immunology*
Histocompatibility Antigens Class II / metabolism
Interferon-gamma / metabolism
Recombinant Fusion Proteins / genetics
Recombinant Fusion Proteins / immunology
Recombinant Fusion Proteins / metabolism
Single-Chain Antibodies / genetics
Single-Chain Antibodies / metabolism
Swine
Swine Diseases / immunology
Swine Diseases / pathology
Swine Diseases / prevention & control*
T-Lymphocytes / immunology
Vaccines, DNA / administration & dosage
Vaccines, DNA / immunology*
Vaccines, Synthetic / administration & dosage
Vaccines, Synthetic / immunology

Substances

Antibodies, Neutralizing
Antibodies, Viral
Epitopes, B-Lymphocyte
Epitopes, T-Lymphocyte
Histocompatibility Antigens Class II
Recombinant Fusion Proteins
Single-Chain Antibodies
Vaccines, DNA
Vaccines, Synthetic
Interferon-gamma